Public-Private Partnership

As part of the NIH HEAL (Helping to End Addiction Long-termSM) Initiative, NIH is working with the U.S. Food and Drug Administration (FDA) and private sector experts to identify areas of opportunity to advance pharmacological treatments for pain and addiction. Through a series of meetings in 2017, NIH worked with experts from across government, industry and academia to determine the pharmacological areas that could be best addressed through public-private partnerships. High priority efforts emerged:

  • Identify potential new uses for existing or abandoned medications that were not effective for other conditions, but may be useful in treating addiction, overdose, or pain.
  • Facilitate sharing data to focus future resources and research and spur innovation in developing new pain medications.
  • Develop methods to objectively measure pain in patients, and to identify biomarkers for more rapid discovery, development and approval of new medications.
  • Establish new clinical trial networks with innovative study design to accelerate drug development for patients with high unmet needs for treatment.

Read the full research plan

This page last reviewed on November 29, 2018